Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07108270) titled 'A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: GlaxoSmithKline
Condition:
Neoplasms, Endometrial
Intervention:
Biological: Dostarlimab
Drug: Carboplatin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 30, 2025
Target Sample Size: 30
To know more, visit https://clinicaltrials.gov/ct...